ModifiedAmbetter NevadaPolicy CP.MP.62

Hyperhidrosis Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.62 alerts

Get alerted when Policy CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity and coverage criteria for iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy for primary hyperhidrosis. It also identifies microwave therapy and liposuction as a sole treatment as unsupported by sufficient peer-reviewed evidence.

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeModified

Effective DateN/A

Last ReviewNov 1, 2025

Next Review DateN/A

Key ActionBefore iontophoresis, document failed conservative management with prescription aluminum chloride hexahydrate or a severe rash from topical agents.

SourceLink

POLICY UPDATE CHANGES

The November 2025 revision removed the requirement that conservative treatment have been tried for six months.

The November 2025 revision removed the criterion concerning being unresponsive or unable to tolerate at least one pharmacotherapy.

The November 2025 revision removed the note under the endoscopic thoracic sympathectomy criteria regarding the standard line of medical therapy.

The November 2025 revision removed the description that sweating occurs in response to heat exposure or exercise.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedAmbetter NevadaPolicy CP.MP.62

Hyperhidrosis Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.62 alerts

Get alerted when Policy CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeModified

Effective DateN/A

Last ReviewNov 1, 2025

Next Review DateN/A

Key ActionBefore iontophoresis, document failed conservative management with prescription aluminum chloride hexahydrate or a severe rash from topical agents.

SourceLink

POLICY UPDATE CHANGES

The November 2025 revision removed the requirement that conservative treatment have been tried for six months.

The November 2025 revision removed the criterion concerning being unresponsive or unable to tolerate at least one pharmacotherapy.

The November 2025 revision removed the note under the endoscopic thoracic sympathectomy criteria regarding the standard line of medical therapy.

The November 2025 revision removed the description that sweating occurs in response to heat exposure or exercise.

Iontophoresis contraindications

>55 bpmETS resting heart rate

<28ETS body mass index

<25 yearsUsual ETS patient age

3Treatment modalities with criteria

2Coverage precedence reminders

Medical Necessity Criteria

Iontophoresis

Covered as medically necessary when ALL of the following are met:

Clinical indication: Diagnosis of primary hyperhidrosis.

Clinical impact: Medical complications, such as skin maceration with secondary skin infections, or significant constant disruption of professional and/or social life caused by excessive sweating.

Examples include recurrent changing of clothes or effects on job or social function.

Conservative treatment failure: Failed a trial of conservative management, including adherent application of aluminum chloride hexahydrate (prescription Drysol), or topical agents resulted in a severe rash.

No contraindications: None of the following contraindications are present: cardiac pacemaker, cardiac arrhythmias, pregnancy, metal implants depending on size and position, or epilepsy.

Surgical excision of axillary sweat glands

Covered as medically necessary when ALL of the following are met:

Incorporated iontophoresis criteria: Meets all iontophoresis criteria in I.A. through I.D.

Disease severity: Persistent and severe primary hyperhidrosis.

Botulinum toxin failure: Failed a trial of botulinum toxin.

Endoscopic thoracic sympathectomy for palmar or palmar and axillary hyperhidrosis

Covered as medically necessary when ALL of the following are met:

Incorporated iontophoresis criteria: Meets all iontophoresis criteria in I.A. through I.D.

Resting heart rate is greater than 55 beats per minute.> 55 beats per minute

Age and symptom onset: Hyperhidrosis symptoms started at an early age, usually before 16 years, and surgery is requested for a young member/enrollee, usually before 25 years of age.Usually symptom onset < 16 years; usually surgery age < 25 years

Body mass index is less than 28.< 28

Microwave therapy and liposuction used as the sole method of removing axillary sweat glands, along with other treatments for hyperhidrosis, lack sufficient evidence in the published peer-reviewed literature to support their use.

Codes and Clinical Thresholds

CPT CodesCPT

11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair.
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair.
15877*	Suction assisted lipectomy; trunk.
15878*	Suction assisted lipectomy; upper extremity.
32664	Thoracoscopy, surgical; with thoracic sympathectomy.
97024*	Application of a modality to 1 or more areas; diathermy (eg, microwave).
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes

Resting Heart Rate for ETS

Required resting heart rate> 55 beats per minute

Applies toEndoscopic thoracic sympathectomy (ETS)

Policy criterionThe member/enrollee must have a resting heart rate greater than 55 beats per minute.

Body Mass Index for ETS

Required body mass index< 28

Applies toEndoscopic thoracic sympathectomy (ETS)

Policy criterionThe member/enrollee's body mass index must be less than 28.

Documentation and Coverage Actions

Note

Review Applicable Medicare Guidance

For Medicare members/enrollees, review all applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Medicare Coverage Articles before applying this policy’s criteria.

Refer to the CMS website for current Medicare coverage guidance.
State Medicaid coverage provisions take precedence when they conflict with this clinical policy.

Step Therapy

Conservative Management Required Before Iontophoresis

Before iontophoresis is authorized, document a failed trial of conservative management or that topical agents caused a severe rash.

Document adherent application of aluminum chloride hexahydrate, such as prescription Drysol.
If topical agents were not tolerated, document the resulting severe rash.

Clinical Background

Hyperhidrosis is excessive sweating beyond the amount needed to maintain normal body temperature. Primary focal hyperhidrosis is idiopathic and commonly affects the axillae, palms, or feet; excessive sweating may cause visible perspiration, emotional distress, clothing damage, and occupational or social impairment.

Secondary hyperhidrosis may result from medications or an underlying disease or condition and is generally managed by addressing the underlying cause. Endoscopic thoracic sympathectomy (ETS) is an invasive treatment that interrupts the upper thoracic sympathetic chain and is considered a last resort because it may cause serious, irreversible compensatory sweating and other effects, including hypotension, arrhythmia, and heat intolerance.

Key Terms

Hyperhidrosis

DefinitionExcessive sweating beyond a level required to maintain normal body temperature.

Clinical featureSweating exceeds the amount needed to maintain normal body temperature.

Condition describedHyperhidrosis.

Primary Focal Hyperhidrosis

DefinitionIdiopathic excessive sweating induced by sympathetic hyperactivity in selected areas and not associated with an underlying disease process.

Common sitesUnderarms (axillary), hands (palmar), and feet (plantar).

Clinical characteristic

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeModified

Effective DateN/A

Last ReviewNov 1, 2025

Next Review DateN/A

Key ActionBefore iontophoresis, document failed conservative management with prescription aluminum chloride hexahydrate or a severe rash from topical agents.

SourceLink

On This Page

Sleep sweating: Reports no sweating during sleep.None during sleep

Comorbidities: Has no significant comorbidities.

Disease severity: Persistent and severe primary hyperhidrosis.

Prior treatment failure

Iontophoresis failure: Failed iontophoresis.
Botulinum toxin failure: Failed a trial of botulinum toxin for predominantly axillary hyperhidrosis.

Risk counseling: Has been counseled on the risks of the procedure.

Usual Age at Symptom Onset for ETS

Usual symptom-onset ageUsually < 16 years

Applies toEndoscopic thoracic sympathectomy (ETS)

Policy criterionHyperhidrosis symptoms must have started at an early age, usually before 16 years.

Usual Age for ETS Request

Usual age for surgery requestUsually < 25 years

Applies toYoung member/enrollee requesting endoscopic thoracic sympathectomy (ETS)

Policy criterionSurgery is requested for a young member/enrollee, usually before 25 years of age.

Step Therapy

Botulinum Toxin Trial Required Before Excision

Surgical excision of axillary sweat glands requires fulfillment of all iontophoresis criteria, persistent and severe primary hyperhidrosis, and failure of a botulinum toxin trial.

Document the failed botulinum toxin trial.
Do not authorize excision when the required iontophoresis criteria or botulinum toxin prerequisite is not met.

Unsupported block type: step_therapy

Documentation Required

Clinical Eligibility Documentation

The clinical record must establish the diagnosis, severity and impact of hyperhidrosis, contraindication screening, and the required treatment-failure history for the requested service.

Document primary hyperhidrosis.
Document medical complications, such as skin maceration with secondary skin infections, or significant constant disruption of professional and/or social life caused by excessive sweating.
For excision or ETS, document persistent and severe primary hyperhidrosis and the applicable failed-treatment trial.
For iontophoresis and procedures requiring the iontophoresis prerequisites, document absence of cardiac pacemaker, cardiac arrhythmias, pregnancy, disqualifying metal implants based on size or position, and epilepsy.

Denial Risk

Iontophoresis Criteria Not Met

Iontophoresis is not medically necessary when any required eligibility criterion is absent or a contraindication is present.

Deny when primary hyperhidrosis is not documented.
Deny when qualifying complications or significant constant professional/social disruption is not documented.
Deny when conservative management was not adequately tried and no severe topical-agent rash is documented.
Deny when the member has a cardiac pacemaker, cardiac arrhythmias, is pregnant, has a disqualifying metal implant, or has epilepsy.

Denial Risk

Surgical Eligibility Criteria Not Met

Surgical excision and ETS are not medically necessary when their required prerequisites, clinical eligibility criteria, or treatment-failure documentation are missing.

For axillary sweat-gland excision, deny when all iontophoresis criteria are not met, primary hyperhidrosis is not persistent and severe, or a botulinum toxin trial has not failed.
For ETS, deny when the iontophoresis criteria, required clinical criteria, counseling, or required failure of iontophoresis or botulinum toxin for predominantly axillary disease is not documented.

Denial Risk

Unsupported Treatment Approach

There is insufficient evidence in the peer-reviewed literature to support other hyperhidrosis treatments identified by this policy, including microwave therapy or liposuction used as the sole method of removing axillary sweat glands.

Microwave therapy, including transcutaneous microwave ablation, is subject to a noncoverage or denial risk under this policy.
Liposuction is not supported when used as the sole axillary sweat-gland removal method.
FDA approval of a device does not establish coverage for all hyperhidrosis sites or indications; the miraDry System is indicated for primary axillary hyperhidrosis, not other body areas or generalized hyperhidrosis.

Visible, excessive sweating of at least six months' duration without apparent cause.

Secondary Hyperhidrosis

DefinitionHyperhidrosis caused by drugs or underlying diseases or conditions.

Usual distributionUsually generalized or craniofacial sweating.

Examples of causesTricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), febrile diseases, diabetes mellitus, or menopause.

Endoscopic Thoracic Sympathectomy (ETS)

DefinitionAn invasive procedure intended to arrest the symptoms of hyperhidrosis.

ProcedureInterrupts the upper thoracic sympathetic chain through clipping, cauterization, or cutting.

Clinical roleConsidered a last resort because of potentially serious, irreversible compensatory sweating and other effects such as extreme hypotension, arrhythmia, and heat intolerance.